Clinical trials: Asymptomatic COVID-19
Covid19
Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test
The INDICAID™ Rapid Antigen Test was used in real-world outbreak testing. The antigen test was used together with PCR testing. This study was designed to evaluate whether the addition of a rapid antigen test decreased time to…
- Trial name
- NCT04904510
- Testing
- INDICAID™ COVID-19 Rapid Antigen Test
- Where
- United States
- Volunteers
- 297 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Sarcopenia
Integrated Physical Training With Protein Diet in Older Adults With Sarcopenia Symptoms.
Sarcopenia is the major health concern and common consequence of COVID-19 in the aging population. Moreover, this clinical condition has not been considered in usual physical rehabilitation practice, and its optimal protein…
- Trial name
- NCT05224453
- Testing
- Physical training and high protein diet, Physical training and low protein diet
- Where
- Saudi Arabia
- Volunteers
- 76 people
- Sponsor
- Prince Sattam Bin Abdulaziz University
SARS CoV 2 Infection
Rutgers Pilot for PREDICT- Patient POC Test
A pilot study was initiated to assess feasibility of testing asymptomatic dental patients presenting to the Oral Medicine Clinic at Rutgers School of Dental Medicine for SARS-CoV-2 viral antigen using a point-of-care (POC) Rapid…
- Trial name
- NCT05612724
- Testing
- Testing for SARS CoV2 Antigen
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
SARS-CoV2 Infection
Rutgers Pilot for PREDICT- Patient LAB Test
A pilot study was initiated to assess feasibility of testing asymptomatic dental patients presenting to the Oral Medicine Clinic at Rutgers School of Dental Medicine for SARS-CoV-2 viral RNA using an FDA approved RT-PCR test for…
- Trial name
- NCT05607043
- Testing
- Testing for SARS CoV2 RNA
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients
The purpose of the study is to compare the efficacy of anti-COVID-19 immune globulin (human) 20% (C19-IG 20%) (2 doses) versus placebo with regard to the percentage of asymptomatic participants who remain asymptomatic, i.e., who…
- Trial name
- COVID-19 (NCT04847141)
- Testing
- C19-IG 20%, 0.9% Sodium chloride
- Where
- 12 sites in Spain
- Volunteers
- 465 people
- Sponsor
- Grifols Therapeutics LLC
COVID
Prophylactic Ivermectin in COVID-19 Contacts
asymptomatic family close contact of confirmed COVID -19 patient will receive prophylactic ivermectin and will be followed up for 14 days for any symptoms \& diagnosis of COVID -19
- Trial name
- NCT04422561
- Testing
- Ivermectin Tablets
- Where
- Egypt
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Healthy Participants
COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay
Primary Objectives: Cohort A: To evaluate the efficacy of REGN10933+REGN10987 compared to placebo in preventing symptomatic SARS-CoV-2 infection (broad-term) confirmed by RT-qPCR Cohort A and Cohort A1: To evaluate the safety and…
- Trial name
- NCT04452318
- Testing
- REGN10933 + REGN10987
- Where
- 134 sites in United States, Moldova and 1 more
- Volunteers
- 3,303 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Sars-CoV2, COVID-19
Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19
The objective of this study is to evaluate the efficacy of oral favipiravir plus standard of care treatment (SOC) compared with placebo plus SOC in reducing the duration of shedding of SARS-CoV2 virus in patients with mild or…
- Trial name
- NCT04346628
- Testing
- Favipiravir, Standard of care treatment
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- Stanford University